Anti-idiotype Antibody Production
Creative Diagnostics provides a full range of service in custom anti-idiotype antibodies (anti-IDs) to support your new monoclonal antibody drugs development. At Creative Diagnostics, our scientists utilize the proprietary technology to guarantee the high specificity and affinity of anti-idiotypic antibody, including magic adjuvant and immune mediators, super-sensitive hybridoma screening, and optimal clone selection processes. We have accomplished 95% success rate of anti-IDs antibody development for our customers.
The idiotype represents the complementarity determining regions (CDR) of an antibody, including the unique antigen binding site, and the combination of epitopes within the idiotype is unique for each antibody. When one antibody binds to one idiotope of another antibody it is referred to as an anti-idiotypic antibody (anti-ID). These highly specialized anti-idiotypic antibodies have become a powerful tool for antibody drug pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity studies.
Features of Our Anti-IDs Antibodies Service:
- High specificity and affinity antibodies to your targets
- Proven track record - 95% success rate of anti-IDs development
- Fast turnaround time: 3.5 – 4.0 months
- Optimal clone selection: antigen ligand blocking, epitope binning and antibody pairing
- Generation of non-inhibitory and drug-target complex antibodies
- Fab and F(ab)2 formats with a choice of detection tags
- Conversion to full immunoglobulin with a choice of isotype
- Antibodies sequenced for long-term security of supply
- Readily integrated downstream antibody drug PK/PD and immunogenicity assay
Anti-idiotype Antibody Production Packages
Anti-idiotypic antibodies that recognize an antigen-combining site of an antibody can mimic the structure and/or function of certain nominal antigens. This feature makes them especially useful in unwanted immunogenicity assessment. For system suitability controls, the FDA recommends that a positive control antibody, either mono- or polyclonal, used at development and validation of immune assays for assessment of the immunogenicity of therapeutic protein products during clinical trials.
Creative Diagnostics also provides immunogenicity testing of antibody drugs:
A number of various assay formats and platforms are available that can be employed for immunogenicity assessment.
Our services include but not limited to:
| Type of assay | |
| Binding Assays of Anti-IDs Antibodies | Enzyme-linked immunosobent assay (ELISA) |
| Electrochemiluminescence immunoassay (ECLIA) | |
| Radioimmunoprecipitation assay (RIPA) | |
| Surface plasmon resonance immunoassay (SPRIA) | |
| Neutralization Assays of Anti-IDs Antibodies | In vitro cell - based bioassays |
| Competitive ligand - binding assays (CLBAs) | |
Both assay types can be used together for the complete characterization of the antibody response against the antibody drugs.